• Adolescent and Young Adult (AYA) guidelines
• COSA guidelines for fertility preservation for people with cancer
  • Appendices
    • Additional resources
    • Guideline development process
    • COSA Fertility Preservation Guidelines Working Group
  • Conception
    • Assisted reproduction and risk of cancer recurrence
    • Interrupting hormone therapy to conceive
  • Contraception
    • Contraception after cancer treatment
    • Cancer Fertility Preservation
  • Discussing Risk
    • Health professional awareness
    • Reproductive concerns
    • Role of oncology services
  • Impact on fertility
    • Ovarian function
    • Pregnancy and live birth
    • Testicular function
  • Pubertal development
  • Options for treatment
    • Embryo cryopreservation
    • Oocyte cryopreservation
    • Safety of ovarian stimulation
    • Ovarian suppression with GnRH analogues
    • Ovarian tissue cryopreservation
    • Ovarian transposition
    • Sperm cryopreservation
    • Testicular biopsy
  • Pregnancy
    • Pregnancy and risk of cancer recurrence
    • Risk of pregnancy complications
  • Psychological support
    • Decision making
    • Fertility counselling
  • Referral and service provision
    • Referral rates and decisional conflict
    • Oncofertility service provision
    • Referral pathways
  • Summary of recommendations
• National Cervical Screening Program
  • Appendices
    • Appendix C
    • Appendix G
    • Appendix I
    • Appendix B
    • Appendix A
    • Appendix F
    • Appendix J
    • Appendix H
    • Appendix D
    • Appendix E
  • 5. Benefits, harms and cost-effectiveness in renewed National Cervical Screening Program (NCSP)
  • 1. Cervical cancer in Australia
  • 7. Colposcopy
    • Colposcopy data for the National Cancer Screening Register
    • Supplement. Colposcopy information for discussion with patient
    • Supplement. Colposcopy technologies and documentation
    • Colposcopy terminology
    • History, examination and investigation
    • Principles of practice
    • Quality improvement in colposcopy
    • Colposcopy and treatment
  • Foreword
  • 12. HPV screening strategies for Aboriginal and Torres Strait Islander women
  • Introduction
  • Cervical Cancer Screening Guideline July 2022 Updates - PDFs
  • 8. Management of discordant colposcopic impression, histopathology and referral LBC prediction
    • Management of discordant colposcopic impression, histopathology and referral LBC prediction
    • Normal colposcopic findings following LBC prediction of Negative, LSIL or HSIL
    • Type 3 TZ (previously termed ‘unsatisfactory’) colposcopy following LBC prediction of Negative, LSIL or HSIL
  • 10. Management of histologically confirmed high-grade squamous abnormalities
    • Diagnosis of high-grade squamous abnormalities
    • Management of histologically confirmed high-grade squamous abnormalities
    • Test of Cure after treatment for HSIL (CIN2/3)
    • Treatment of high-grade squamous abnormalities
  • 11. Management of glandular abnormalities
    • Follow-up after excisional treatment for AIS
    • Investigation of cytological glandular abnormalities
    • Management of histologically confirmed high-grade glandular abnormalities
  • 9. Management of histologically confirmed low-grade squamous abnormalities
  • 6. Management of oncogenic HPV test results
    • Flowcharts: Management of oncogenic HPV test results
    • Management of HPV test results
    • Medical Services Advisory Committee recommendations for HPV testing
    • Oncogenic HPV types 16 and/or 18
    • Oncogenic HPV types not 16/18
    • Oncogenic HPV types not detected
    • Screening in women older than 75
    • Self-collected vaginal samples
    • Women undergoing exit testing
  • 19. Psychosocial care
  • 13. Screening after total hysterectomy
  • 17. DES-exposed women
  • 16. Screening in immune-deficient women
  • 14. Screening in pregnancy
  • 18. Signs and symptoms of cervical cancer
    • Investigation of abnormal vaginal bleeding
    • Investigations of other symptoms: vaginal discharge and deep dyspareunia
  • Summary of recommendations
  • 3. Terminology
    • Cytology and AMBS 2004 terminology for reporting
    • Histopathology
    • HPV testing terminology
    • Preparation of cervical screening reports
    • Supplement: Sample reports
  • 2. The rationale for primary HPV screening
  • 20. Transition to the renewed National Cervical Screening Program
  • 4. Unsatisfactory cervical screening results
  • 15. Women experienced early sexual activity or victims of abuse
• Liver cancer clinical guidelines
  • Hepatocellular Carcinoma
• Neuroendocrine Neoplasms (NENs) Clinical Guidelines
  • Neuroendocrine Neoplasms (NENs) Clinical Guidelines